Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?

Daoud, Ahmed; Teeter, Larry D.; Ghobrial, Rafik M.; Graviss, Edward A.; Mogawer, Sherif; Sholkamy, Amany; Elshazli, Mostafa; Gaber, A. Osama

doi:10.1016/j.transproceed.2018.04.038

Cited by 7 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No statistically differences in 1-, 3-, and 5-year survival rates were reported between the three groups. In addition, Zhu et al [ 29 ] concluded that LDLT outcomes are similar to DDLT outcomes, which was also supported by the same outcomes both from Western [ 21 , 30 ] and Asian [ 13 ] centers' reported data.…”

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 77%

“…In addition, with the advantage of LDLT, some centers began to push the limits of size and number with no invasion of major vascular structures and no evidence of extrahepatic disease, as reported in 2007 by Haberal et al [ 35 ] from Türkiye. [ 30 ] With an overall 50.3% survival rate at 5 years, this report was promising for future studies.…”

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 79%

“…[ 13 - 27 ] The review and meta-analysis by Zhu et al [ 29 ] conducted in 5 European, 11 North American, 2 South American, 10 Asian, and 1 African countries with 5,379 patients, concluded that surgeons expanded the criteria for LDLT in HCC patients in the region with insufficient deceased donation. Unfortunately, Daoud et al [ 30 ] from Houston Methodist Hospital, Texas, US, reported the data from 11,928 LT for HCC patients from the United Network for Organ Sharing (UNOS) between 2002 and 2013. In this analysis, less than 1% (82) of cases were beyond the Milan and USCF criteria, and around 2% (291) were beyond the MC and within the USCF.…”

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Yankol

2024

Sisli Etfal

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, with increasing incidence. There are different treatment options, but only 30%-40% of HCC cases are diagnosed at an early stage for curative treatment. With the implementation of Milan Criteria for liver transplantation (LT) in HCC cases and its use for organ allocation with successful outcomes, LT has become an optimal treatment. Seeking new criteria for LT and developing updated algorithms for HCC treatment has become a hot topic nowadays. With the experience in living donor liver transplantation (LDLT), especially in Asian countries, LDLT was established and adopted with different criteria for HCC treatment, especially including criteria beyond Milan's size and number of tumors. Living donor grafts are uniquely different than deceased donor grafts as they are not considered a public resource. A living donor graft is rather a private gift intended for a specific recipient. Living donor livers are not limited by organ allocation systems, and this significant advantage of LDLT has opened new frontiers in the treatment of HCC. Improvements in LDLT have had remarkable parallel effects in the successful treatment of HCC as supported by a growing body of literature in the past decade.

show abstract

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 77%

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 79%

Section: Living Donor Liver Transplantation In Hcc Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Yankol

2024

Sisli Etfal

View full text Add to dashboard Cite

show abstract

“…Fifty-eight studies that compared the Milan criteria with other criteria were included in the study. Of these, 41 studies compared the Milan and UCSF criteria 33–45 , 47–51 , 53 , 55–60 , 63 , 64 , 67 , 68 , 70–73 , 76–79 , 83 , 85 , 86 , 90 , 16 studies compared the Milan and UPTS criteria 46 , 52 , 54 , 59 , 61 , 62 , 65 , 66 , 68 , 73 , 74 , 78 , 83 , 84 , 86 , 87 , seven studies compared the Milan and AFP criteria 69 , 75 , 80–82 , 87 , 88 , four studies compared the Milan and MT2 criteria 82 , 87–89 , one study compared the UPTS and MT2 criteria 87 , one study compared the UPTS and AFP criteria 87 , three studies compared the MT2 and AFP criteria 82 , 87 , 88 , and six studies compared the UCSF and UPTS criteria 59 , 68 , 73 , 78 , 83 , 86 .…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Patients with hepatocellular carcinoma (HCC) are selected for transplantation if they have a low tumour burden and low risk of recurrence. The morphometric Milan criteria have been the cornerstone for patient selection, but dynamic morphological and biological tumour characteristics surfaced as an encouraging tool to refine the selection of patients with HCC and to support the expansion of the Milan criteria. The outcomes of the most prevalent models that select patients with HCC for liver transplantation were analysed in this study, which aimed to identify the selection model that offered the best recurrence-free and overall survival after transplantation. Methods Studies that compared Milan, University of California San Francisco (UCSF), up-to-seven (UPTS), alpha-fetoprotein (AFP), and MetroTicket 2.0 (MT2) models were included. One-year, 3-year, and 5-year recurrence-free and overall survival rates of patients selected for transplantation using different models were analysed. Results A total of 60 850 adult patients with HCC selected for liver transplantation using Milan, UCSF, UPTS, AFP, or MT2 criteria were included. Patients selected for transplantation using the MT2 model had the highest 1-, 3-, and 5-year recurrence-free survival. In addition, patients selected for transplantation using MT2 criteria had the best 1- and 3-year overall survival, whereas patients selected for transplantation using the Milan criteria had the best 5-year overall survival rates. Conclusion The MT2 model offered the best post-transplant outcomes in patients with HCC, highlighting the importance of considering tumour morphology and biology when selecting patients with HCC for liver transplantation.

show abstract

An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer

Fong

Moore

et al. 2021

Computerized Medical Imaging and Graphics

View full text Add to dashboard Cite

Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?

Cited by 7 publications

References 6 publications

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis

An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer

Contact Info

Product

Resources

About